US stock futures flounder amid tech weakness, Fed caution
David Sponsel, Executive Vice President of Sales at Alphatec Holdings , Inc. (NASDAQ:ATEC), recently sold 36,256 shares of the company’s common stock. The shares were sold at a weighted average price of $11.42, totaling approximately $414,043. Following this transaction, Sponsel holds 735,074 shares directly. According to InvestingPro data, ATEC’s stock has shown remarkable momentum, surging 92.7% over the past six months, with the current trading price at $12.14.
The sale was conducted under a Rule 10b5-1 trading plan, which was established on September 11, 2024, to cover tax obligations associated with the vesting of restricted stock units. The shares were sold in multiple transactions, with prices ranging from $11.28 to $11.58. Sponsel has committed to providing detailed information regarding the specific number of shares sold at each price, upon request. InvestingPro analysis shows ATEC maintains a "GOOD" overall financial health score, with analyst price targets ranging from $10 to $22.50. Access the comprehensive Pro Research Report for deeper insights into ATEC’s valuation and growth prospects.
In other recent news, Alphatec Holdings reported strong preliminary financial results for the fourth quarter and full year of 2024, with a 27% increase in total revenue for the full year. The company’s growth was driven by a 29% rise in surgical revenue due to a 19% increase in surgical volume and an 8% increase in average revenue per procedure. Alphatec also announced a significant increase in its cash balance, partly due to a $50 million term loan expansion.
Analyst David Saxon from Needham has raised the price target on Alphatec, maintaining a Buy rating, highlighting the company’s robust surgical growth. Piper Sandler analysts also expressed optimism for Alphatec, anticipating positive fiscal year outlooks.
Looking ahead, Alphatec anticipates full-year 2025 revenue to reach $732 million, which would represent a 20% growth compared to 2024. This projection includes surgical revenue of approximately $657 million and EOS revenue around $75 million. The company also expects to achieve positive free cash flow with an adjusted EBITDA of $75 million for the year.
In other company news, Dave Demski, who holds board membership at Alphatec, was appointed as an independent director at Paragon 28, expanding their Board of Directors to nine members. These are among the recent developments for Alphatec Holdings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.